Brodalumab-an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis

Bibliography

• Langley RGB, Krueger GG, Griffiths CEM. Psoriatic arthritis and psoriasis: classification, clinical features, pathophysiology, immunology, genetics. Ann Rheum Dis 2005;64:18-23
   Web of Science ®Google Scholar
• Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53(4):573
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5(12):1424-9
   PubMed Web of Science ®Google Scholar
• Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief 2012(94):1-8
   PubMedGoogle Scholar
• Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011;34(2):149-62
   PubMed Web of Science ®Google Scholar
• Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 2011;23(7):1069-75
   PubMed Web of Science ®Google Scholar
• Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emer Microbes Infect 2013;2:e60
   PubMed Web of Science ®Google Scholar
• Van den berg WB, Mcinnes IB. Th17 cells and IL-17 a: focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013;43(2):158-70
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82
   PubMed Web of Science ®Google Scholar
• Huang H, Kim HJ, Chang EJ, et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ 2009;16:1332-43
   PubMed Web of Science ®Google Scholar
• Maddur S, et al. Review: Th17 cells. Am J Pathol 2012;181(1):03-44
   Google Scholar
• Xiao S, Yosef N, Yang J, et al. Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 2014;40(4):477-89
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128(5):1207-11
   PubMed Web of Science ®Google Scholar
• Bluett J, Barton A. What have genome-wide studies told us about psoriatic arthritis? Curr Rheumatol Rep 2012;14(4):364-8
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012;359(1-2):419-29
   PubMed Web of Science ®Google Scholar
• Attur MG, Patel RN, Abramson SB, Amin AR. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997;40(6):1050-3
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52(1):65-70
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Kokubu F, Fujita J, et al. Role of interleukin-17F in asthma. Inflamm Allergy Drug Targets 2009;8(5):383-9
   PubMedGoogle Scholar
• Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008;205(5):1063-75
   PubMed Web of Science ®Google Scholar
• Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013;72(6):863-9
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9
   PubMed Web of Science ®Google Scholar
• Salinger DH, Martin DA, Gibbs M. Exposure-response modeling of phase 1 data to inform phase 2 dose selection: a case study using AMG 827 in psoriasis. 40th Annual Meeting of the American College of Clinical Pharmacology; 11 – 13 September 2011; Chicago, IL
   Google Scholar
• Martin DA, Churchill M, Flores-suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013;15(5):R164
   PubMed Web of Science ®Google Scholar
• Osamu N, Hirotaka N, Koji S, Kenji T. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study. J Dermatol Sci 2014;75(3):201-4
   PubMed Web of Science ®Google Scholar
• Endres CJ, Salinger DH, Köck K, et al. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies. J Clin Pharmacol 2014;54(11):1230-8
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181-9
   PubMed Web of Science ®Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014;71(6):1183-90
   PubMed Web of Science ®Google Scholar
• Barber J. Amgen, AstraZeneca’s brodalumab meets primary endpoints of third Phase III trial in moderate-to-severe-plaque psoriasis. First Word Pharma, 2014. Web. 2015
   Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370(24):2295-306
   PubMed Web of Science ®Google Scholar
• Pavelka K, Chon Y, Newmark R, et al. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability and efficacy of Brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthrit Rheum 2012;64(10
   Google Scholar
• Abstract at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting. 9 – 14 November 2012; Washington, DC
   Google Scholar
• Martin DA, Churchill M, Flores-suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013;15(5):R164
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Vermeire S, et al. 2012 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s disease. Gastroenterology 2012;143
   Google Scholar
• Busse WW, Holgate ST, Kerwin EM, et al. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with moderate to severe asthma. J Allergy Clin Immun 2013;131(2):AB230.
   Google Scholar
• Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat 2013;24(3):169-78
   PubMed Web of Science ®Google Scholar
• Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011;165(5):1109-17
   PubMed Web of Science ®Google Scholar
• Mcinnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382(9894):780-9
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264-72
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2013;52:3279-89
   Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373(9664):633-40
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374(9685):210-21
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde Dv, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58(11):3319-29
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30(12):2563-71
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton A, Sweeting MJ, et al. Anti-TNF antibody therpay in rheumatoid arthritis and the risk of serious infections and malignancies: A systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
   PubMed Web of Science ®Google Scholar